Cancer Research The Future of Cancer Research: Science and Patient Impact
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Frasor, J.
Right arrow Articles by Katzenellenbogen, B. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Frasor, J.
Right arrow Articles by Katzenellenbogen, B. S.
[Cancer Research 64, 1522-1533, February 15, 2004]
© 2004 American Association for Cancer Research

Endocrinology

Selective Estrogen Receptor Modulators

Discrimination of Agonistic versus Antagonistic Activities by Gene Expression Profiling in Breast Cancer Cells

Jonna Frasor1, Fabio Stossi1, Jeanne M. Danes1, Barry Komm2, C. Richard Lyttle2 and Benita S. Katzenellenbogen1

1 Department of Molecular and Integrative Physiology, University of Illinois and College of Medicine, Urbana, Illinois, and 2 Women’s Health Research Institute, Wyeth Research, Collegeville, Pennsylvania

Selective estrogen receptor modulators (SERMs) such as tamoxifen are effective in the treatment of many estrogen receptor-positive breast cancers and have also proven to be effective in the prevention of breast cancer in women at high risk for the disease. The comparative abilities of tamoxifen versus raloxifene in breast cancer prevention are currently being compared in the Study of Tamoxifen and Raloxifene trial. To better understand the actions of these compounds in breast cancer, we have examined their effects on the expression of ~12,000 genes, using Affymetrix GeneChip microarrays, with quantitative PCR verification in many cases, categorizing their actions as agonist, antagonist, or partial agonist/antagonist. Analysis of gene stimulation and inhibition by the SERMs trans-hydroxytamoxifen (TOT) and raloxifene (Ral) or ICI 182,780 (ICI) and by estradiol (E2) in estrogen receptor-containing MCF-7 human breast cancer cells revealed that (a) TOT was the most E2-like of the three compounds, (b) all three compounds either partially or fully antagonized the action of E2 on most genes, with the order of antagonist activity being ICI > Ral > TOT, (c) TOT and Ral, but not ICI, displayed partial agonist/partial antagonist activity on a number of E2-regulated genes, (d) several stimulatory cell cycle-related genes were down-regulated exclusively by ICI, (e) the estrogen-like activity of Ral nearly always overlapped with that of TOT, indicating that Ral has little unique agonist activity different from that of TOT, and (f) some genes were specifically up-regulated by TOT but not Ral, ICI, or E2. Hence, gene expression profiling can discern fundamental differences among SERMs and provides insight into the distinct biologies of TOT, Ral, and ICI in breast cancer.




This article has been cited by other articles:


Home page
 EndocrinologyHome page
P. D. Alfinito, X. Chen, J. Atherton, S. Cosmi, and D. C. Deecher
ICI 182,780 Penetrates Brain and Hypothalamic Tissue and Has Functional Effects in the Brain after Systemic Dosing
Endocrinology, October 1, 2008; 149(10): 5219 - 5226.
[Abstract] [Full Text] [PDF]

Home page
 Biol. Reprod.Home page
F. Yasuhara, G. R. O. Gomes, E. R. Siu, C. I. Suenaga, E. Marostica, C. S. Porto, and M. F. M. Lazari
Effects of the Antiestrogen Fulvestrant (ICI 182,780) on Gene Expression of the Rat Efferent Ductules
Biol Reprod, September 1, 2008; 79(3): 432 - 441.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. H. Barnett, S. Sheng, T. Howe Charn, A. Waheed, W. S. Sly, C.-Y. Lin, E. T. Liu, and B. S. Katzenellenbogen
Estrogen Receptor Regulation of Carbonic Anhydrase XII through a Distal Enhancer in Breast Cancer
Cancer Res., May 1, 2008; 68(9): 3505 - 3515.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
X. Wang, S. Masri, S. Phung, and S. Chen
The Role of Amphiregulin in Exemestane-Resistant Breast Cancer Cells: Evidence of an Autocrine Loop
Cancer Res., April 1, 2008; 68(7): 2259 - 2265.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
N. Levy, D. Tatomer, C. B. Herber, X. Zhao, H. Tang, T. Sargeant, L. J. Ball, J. Summers, T. P. Speed, and D. C. Leitman
Differential Regulation of Native Estrogen Receptor-Regulatory Elements by Estradiol, Tamoxifen, and Raloxifene
Mol. Endocrinol., February 1, 2008; 22(2): 287 - 303.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
K. J. Higgins, S. Liu, M. Abdelrahim, K. Vanderlaag, X. Liu, W. Porter, R. Metz, and S. Safe
Vascular Endothelial Growth Factor Receptor-2 Expression Is Down-Regulated by 17{beta}-Estradiol in MCF-7 Breast Cancer Cells by Estrogen Receptor {alpha}/Sp Proteins
Mol. Endocrinol., February 1, 2008; 22(2): 388 - 402.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J. Cheng, D. V. Yu, J.-H. Zhou, and D. J. Shapiro
Tamoxifen Induction of CCAAT Enhancer-binding Protein {alpha} Is Required for Tamoxifen-induced Apoptosis
J. Biol. Chem., October 19, 2007; 282(42): 30535 - 30543.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
J. D. Stender, J. Frasor, B. Komm, K. C. N. Chang, W. L. Kraus, and B. S. Katzenellenbogen
Estrogen-Regulated Gene Networks in Human Breast Cancer Cells: Involvement of E2F1 in the Regulation of Cell Proliferation
Mol. Endocrinol., September 1, 2007; 21(9): 2112 - 2123.
[Abstract] [Full Text] [PDF]

Home page
 Biol. Reprod.Home page
E. J Su, Y.-H. Cheng, R. T Chatterton, Z.-H. Lin, P. Yin, S. Reierstad, J. Innes, and S. E Bulun
Regulation of 17-Beta Hydroxysteroid Dehydrogenase Type 2 in Human Placental Endothelial Cells
Biol Reprod, September 1, 2007; 77(3): 517 - 525.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
K. Mita, Z. Zhang, Y. Ando, T. Toyama, M. Hamaguchi, S. Kobayashi, S.-i. Hayashi, Y. Fujii, H. Iwase, and H. Yamashita
Prognostic Significance of Insulin-like Growth Factor Binding Protein (IGFBP)-4 and IGFBP-5 Expression in Breast Cancer
Jpn. J. Clin. Oncol., August 3, 2007; (2007) hym066v1.
[Abstract] [Full Text] [PDF]

Home page
 Nucleic Acids ResHome page
J. R. Schultz-Norton, V. A. Gabisi, Y. S. Ziegler, I. X. McLeod, J. R. Yates, and A. M. Nardulli
Interaction of estrogen receptor {alpha} with proliferating cell nuclear antigen
Nucleic Acids Res., August 1, 2007; 35(15): 5028 - 5038.
[Abstract] [Full Text] [PDF]

Home page
 Physiol. Rev.Home page
N. Heldring, A. Pike, S. Andersson, J. Matthews, G. Cheng, J. Hartman, M. Tujague, A. Strom, E. Treuter, M. Warner, et al.
Estrogen Receptors: How Do They Signal and What Are Their Targets
Physiol Rev, July 1, 2007; 87(3): 905 - 931.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
J. R. Schultz-Norton, K. A. Walt, Y. S. Ziegler, I. X. McLeod, J. R. Yates, L. T. Raetzman, and A. M. Nardulli
The Deoxyribonucleic Acid Repair Protein Flap Endonuclease-1 Modulates Estrogen-Responsive Gene Expression
Mol. Endocrinol., July 1, 2007; 21(7): 1569 - 1580.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
S. M Johnson, M. Maleki-Dizaji, J. A Styles, and I. N H White
Ishikawa cells exhibit differential gene expression profiles in response to oestradiol or 4-hydroxytamoxifen
Endocr. Relat. Cancer, June 1, 2007; 14(2): 337 - 350.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
K.-C. Leung, J. Brce, N. Doyle, H. J. Lee, G. M. Leong, K. Sjogren, and K. K. Y. Ho
Regulation of Growth Hormone Signaling by Selective Estrogen Receptor Modulators Occurs through Suppression of Protein Tyrosine Phosphatases
Endocrinology, May 1, 2007; 148(5): 2417 - 2423.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
F. Andre, C. Hatzis, K. Anderson, C. Sotiriou, C. Mazouni, J. Mejia, B. Wang, G. N. Hortobagyi, W. F. Symmans, and L. Pusztai
Microtubule-Associated Protein-tau is a Bifunctional Predictor of Endocrine Sensitivity and Chemotherapy Resistance in Estrogen Receptor-Positive Breast Cancer
Clin. Cancer Res., April 1, 2007; 13(7): 2061 - 2067.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Fan, P. S. Yan, C. Hartman-Frey, L. Chen, H. Paik, S. L. Oyer, J. D. Salisbury, A. S.L. Cheng, L. Li, P. H. Abbosh, et al.
Diverse Gene Expression and DNA Methylation Profiles Correlate with Differential Adaptation of Breast Cancer Cells to the Antiestrogens Tamoxifen and Fulvestrant
Cancer Res., December 15, 2006; 66(24): 11954 - 11966.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
J M W Gee, V E Shaw, S E Hiscox, R A McClelland, N K Rushmere, and R I Nicholson
Deciphering antihormone-induced compensatory mechanisms in breast cancer and their therapeutic implications
Endocr. Relat. Cancer, December 1, 2006; 13(Supplement_1): S77 - S88.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
B. M. Jaber, T. Gao, L. Huang, S. Karmakar, and C. L. Smith
The Pure Estrogen Receptor Antagonist ICI 182,780 Promotes a Novel Interaction of Estrogen Receptor-{alpha} with the 3',5'-Cyclic Adenosine Monophosphate Response Element-Binding Protein-Binding Protein/p300 Coactivators
Mol. Endocrinol., November 1, 2006; 20(11): 2695 - 2710.
[Abstract] [Full Text] [PDF]

Home page
 ScienceHome page
J. Lamb, E. D. Crawford, D. Peck, J. W. Modell, I. C. Blat, M. J. Wrobel, J. Lerner, J.-P. Brunet, A. Subramanian, K. N. Ross, et al.
The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease.
Science, September 29, 2006; 313(5795): 1929 - 1935.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
A. Howell
Pure oestrogen antagonists for the treatment of advanced breast cancer.
Endocr. Relat. Cancer, September 1, 2006; 13(3): 689 - 706.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
T. Shioda, J. Chesnes, K. R. Coser, L. Zou, J. Hur, K. L. Dean, C. Sonnenschein, A. M. Soto, and K. J. Isselbacher
Importance of dosage standardization for interpreting transcriptomal signature profiles: Evidence from studies of xenoestrogens
PNAS, August 8, 2006; 103(32): 12033 - 12038.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
Y. C. Lim, L. Li, Z. Desta, Q. Zhao, J. M. Rae, D. A. Flockhart, and T. C. Skaar
Endoxifen, a Secondary Metabolite of Tamoxifen, and 4-OH-Tamoxifen Induce Similar Changes in Global Gene Expression Patterns in MCF-7 Breast Cancer Cells
J. Pharmacol. Exp. Ther., August 1, 2006; 318(2): 503 - 512.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. Frasor, E. C. Chang, B. Komm, C.-Y. Lin, V. B. Vega, E. T. Liu, L. D. Miller, J. Smeds, J. Bergh, and B. S. Katzenellenbogen
Gene expression preferentially regulated by tamoxifen in breast cancer cells and correlations with clinical outcome.
Cancer Res., July 15, 2006; 66(14): 7334 - 7340.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Woditschka, J. D. Haag, J. L. Waller, D. M. Monson, A. A. Hitt, H. L. Brose, R. Hu, Y. Zheng, P. A. Watson, K. Kim, et al.
Neu-Induced Retroviral Rat Mammary Carcinogenesis: A Novel Chemoprevention Model for Both Hormonally Responsive and Nonresponsive Mammary Carcinomas.
Cancer Res., July 1, 2006; 66(13): 6884 - 6891.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
F. Stossi, V. S. Likhite, J. A. Katzenellenbogen, and B. S. Katzenellenbogen
Estrogen-occupied Estrogen Receptor Represses Cyclin G2 Gene Expression and Recruits a Repressor Complex at the Cyclin G2 Promoter
J. Biol. Chem., June 16, 2006; 281(24): 16272 - 16278.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
C L Wilson, A H Sims, A Howell, C J Miller, and R B Clarke
Effects of oestrogen on gene expression in epithelium and stroma of normal human breast tissue.
Endocr. Relat. Cancer, June 1, 2006; 13(2): 617 - 628.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
S. Olivier, P. Close, E. Castermans, L. de Leval, S. Tabruyn, A. Chariot, M. Malaise, M.-P. Merville, V. Bours, and N. Franchimont
Raloxifene-Induced Myeloma Cell Apoptosis: A Study of Nuclear Factor-{kappa}B Inhibition and Gene Expression Signature
Mol. Pharmacol., May 1, 2006; 69(5): 1615 - 1623.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
D. M. E. Harvell, J. K. Richer, D. C. Allred, C. A. Sartorius, and K. B. Horwitz
Estradiol Regulates Different Genes in Human Breast Tumor Xenografts Compared with the Identical Cells in Culture
Endocrinology, February 1, 2006; 147(2): 700 - 713.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
J. G. W. Fleming, T. E. Spencer, S. H. Safe, and F. W. Bazer
Estrogen Regulates Transcription of the Ovine Oxytocin Receptor Gene through GC-Rich SP1 Promoter Elements
Endocrinology, February 1, 2006; 147(2): 899 - 911.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
J. D. Yager and N. E. Davidson
Estrogen Carcinogenesis in Breast Cancer
N. Engl. J. Med., January 19, 2006; 354(3): 270 - 282.
[Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
S C J P Gielen, L C M Kuhne, P C Ewing, L J Blok, and C W Burger
Tamoxifen treatment for breast cancer enforces a distinct gene-expression profile on the human endometrium: an exploratory study
Endocr. Relat. Cancer, December 1, 2005; 12(4): 1037 - 1049.
[Abstract] [Full Text] [PDF]

Home page
 Reproductive SciencesHome page
S. C.J.P. Gielen, C. W. Burger, L. C.M. Kuhne, P. Hanifi-Moghaddam, and L. J. Blok
Analysis off Estrogen Agonism and Antagonism of Tamoxifen, Raloxifene, and ICI182780 in Endometrial Cancer Cells: A Putative Role for the Epidermal Growth Factor Receptor Ligand Amphiregulin
Reproductive Sciences, October 1, 2005; 12(7): e55 - e66.
[Abstract] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
J. Frasor, J. M. Danes, C. C. Funk, and B. S. Katzenellenbogen
Estrogen down-regulation of the corepressor N-CoR: Mechanism and implications for estrogen derepression of N-CoR-regulated genes
PNAS, September 13, 2005; 102(37): 13153 - 13157.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
M. Ivanova, K. M. Dobrzycka, S. Jiang, K. Michaelis, R. Meyer, K. Kang, B. Adkins, O. A. Barski, S. Zubairy, J. Divisova, et al.
Scaffold Attachment Factor B1 Functions in Development, Growth, and Reproduction
Mol. Cell. Biol., April 15, 2005; 25(8): 2995 - 3006.
[Abstract] [Full Text] [PDF]

Home page
 J Mol EndocrinolHome page
H K Kinyamu, J Chen, and T K Archer
Linking the ubiquitin-proteasome pathway to chromatin remodeling/modification by nuclear receptors
J. Mol. Endocrinol., April 1, 2005; 34(2): 281 - 297.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
T. Itoh, K. Karlsberg, I. Kijima, Y.-C. Yuan, D. Smith, J. Ye, and S. Chen
Letrozole-, Anastrozole-, and Tamoxifen-Responsive Genes in MCF-7aro Cells: A Microarray Approach
Mol. Cancer Res., April 1, 2005; 3(4): 203 - 218.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. J. Fabian and B. F. Kimler
Selective Estrogen-Receptor Modulators for Primary Prevention of Breast Cancer
J. Clin. Oncol., March 10, 2005; 23(8): 1644 - 1655.
[Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
J A Vendrell, I Bieche, C Desmetz, E Badia, S Tozlu, C Nguyen, J C Nicolas, R Lidereau, and P A Cohen
Molecular changes associated with the agonist activity of hydroxy-tamoxifen and the hyper-response to estradiol in hydroxy-tamoxifen-resistant breast cancer cell lines
Endocr. Relat. Cancer, March 1, 2005; 12(1): 75 - 92.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
R. Varshochi, F. Halim, A. Sunters, J. P. Alao, P. A. Madureira, S. M. Hart, S. Ali, D. M. Vigushin, R. C. Coombes, and E. W.-F. Lam
ICI182,780 Induces p21Waf1 Gene Transcription through Releasing Histone Deacetylase 1 and Estrogen Receptor {alpha} from Sp1 Sites to Induce Cell Cycle Arrest in MCF-7 Breast Cancer Cell Line
J. Biol. Chem., February 4, 2005; 280(5): 3185 - 3196.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
D. G. DeNardo, H.-T. Kim, S. Hilsenbeck, V. Cuba, A. Tsimelzon, and P. H. Brown
Global Gene Expression Analysis of Estrogen Receptor Transcription Factor Cross Talk in Breast Cancer: Identification of Estrogen-Induced/Activator Protein-1-Dependent Genes
Mol. Endocrinol., February 1, 2005; 19(2): 362 - 378.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
M. Karl, M. Potier, I. H. Schulman, A. Rivera, H. Werner, A. Fornoni, and S. J. Elliot
Autocrine Activation of the Local Insulin-Like Growth Factor I System Is Up-Regulated by Estrogen Receptor (ER)-Independent Estrogen Actions and Accounts for Decreased ER Expression in Type 2 Diabetic Mesangial Cells
Endocrinology, February 1, 2005; 146(2): 889 - 900.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
P. Labhart, S. Karmakar, E. M. Salicru, B. S. Egan, V. Alexiadis, B. W. O'Malley, and C. L. Smith
Identification of target genes in breast cancer cells directly regulated by the SRC-3/AIB1 coactivator
PNAS, February 1, 2005; 102(5): 1339 - 1344.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
M. Fan, H. Nakshatri, and K. P. Nephew
Inhibiting Proteasomal Proteolysis Sustains Estrogen Receptor-{alpha} Activation
Mol. Endocrinol., November 1, 2004; 18(11): 2603 - 2615.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2004 by the American Association for Cancer Research.